Latest on Pharmaceutical Industry


Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment

Churchill Pharmaceuticals, LLC announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for YONSA™ (abiraterone acetate), an improved ultramicrosize formulation of abirater..Read More...

Japan to target big increase in use of generic drugs

Japan will target a boost in the use of generic drugs to over 80 percent from the current 56 percent by September 2020, two government sources with direct knowledge of the matter said on Tuesday. The move would save J..Read More...



Pharmaceutical Traceability Forum

Hotel Del Coronado,

Press Releases

NeuroVive to Continue NeuroSTAT® Clinical Development After Positive Outcome in Preclinical and Clinical TBI Studies

NeuroVive Pharmaceutical AB announced positive results from clinical and preclinical studies with its drug NeuroSTAT for the prevention of the sequelae of traumatic brain injury TBI The company is now preparing for the n.. Read More...

ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)

ChemoCentryx Inc a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer announced today that the European Medicines Agency EMA has granted orphan medicinal prod.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics